- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05278156
Effekt, sikkerhed og farmakokinetikundersøgelse af CPL500036 (PDE10A-hæmmer) hos patienter med skizofreni
Fase II, dobbeltblind, randomiseret, placebokontrolleret, parallel gruppe, forsøg for at udforske effektivitet, sikkerhed og farmakokinetik af CPL500036 (PDE10A-hæmmer) hos patienter med en akut forværring af skizofreni
The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A [PDE10A] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Bialystok, Polen, 15-272
- Uniwersytecki Szpital Kliniczny
-
Bolesławiec, Polen, 59-700
- Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
-
Choroszcz, Polen, 16-070
- Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
-
Gmina Świecie, Polen, 86-100
- Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76014
- Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
-
Kyiv, Ukraine, 04080
- Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
-
Kyiv, Ukraine, 08631
- Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
-
Lviv, Ukraine, 79017
- Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
-
Lviv, Ukraine, 79021
- Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
-
Ternopil, Ukraine, 46001
- Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
-
Vinnytsia, Ukraine, 21018
- Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education
-
-
-
-
-
Budapest, Ungarn, H-1083
- Department of Psychiatry and Psychotheraapy of Semmelweis University
-
Budapest, Ungarn, H-1085
- Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
-
Győr, Ungarn, H-9024
- Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
-
Kalocsa, Ungarn, H-6300
- Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
-
Szekszárd, Ungarn, H-7100
- Psychiatry Department of Tolna County Balassa Janos Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- The patient has a primary diagnosis of schizophrenia confirmed by clinical interview [SCID-5-CT].
- Male or female patient aged 18 to 65, inclusive, at Screening.
- The patient's with exacerbation of psychotic symptoms
- The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
- The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
- The patient of childbearing potential willing to use acceptable forms of contraception.
- The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
- The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
- The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.
Exclusion Criteria:
- The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
- Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
- The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
- The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
- The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
- The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
- The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
- The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
- The patient has chronic movement disorder that may interfere with the interpretation of study results.
- The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
- The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
- The patient is considered to be treatment resistant. .
- The patient has received electroconvulsive therapy.
- The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: CPL500036 low dose
Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period. |
CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily. |
|
Eksperimentel: CPL500036 high dose
Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period. |
CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily. |
|
Placebo komparator: Placebo
Patients are to receive placebo administered once dail for 28-days treatment period. |
Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in PANSS Positive Subscale at Week 4.
Tidsramme: Day -1, Week 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 4
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in PANSS Positive Subscale at Week 1, 2 and 3
Tidsramme: Day -1, Week 1, 2 and 3
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2 and 3
|
|
Change From Baseline in PANSS Total Score at Weeks 1, 2, 3, 4
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in PANSS Subscales Using the Marder 5 Factor Model at Weeks 1, 2, 3, and 4
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) Marder 5-Factor Model is a structure used for the Positive and Negative Syndrome Scale (as original PANSS scale), but breaking its 30 items (from positive, negative and general psychopathology groups) into five key symptom domains: Positive (8 items: Range 8-56), Negative (7 items: Range 7-49), Disorganized thoughts (7 items: Range 7-49), Uncontrolled hostility/excitement (4 items: Range 4-28), and Anxiety/depression (4 items: Range 4-28). The higher score in subscale, the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in PANSS General Psychopathology Subscale at Weeks 1, 2, 3 and 4
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Percentage of Clinical Responders Based on the PANSS Total Score.
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. Clinical responder is defined as a ≥ 30% decrease from baseline. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1= normal (not at all ill) and 7 = among the most extremely ill patients. |
Day -1, Week 1, 2, 3 and 4
|
|
Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
CGI-I is a 7 points scale that requires the clinician to assess how much the patient's illness has improved or worsened during treatment. It is a 7-point assessment where 1= Very much improved and 7 = Very much worse |
Day -1, Week 1, 2, 3 and 4
|
|
Percentage of Clinical Responders Based on the CGI-I Score.
Tidsramme: Day -1, Week 1, 2, 3 and 4
|
Day -1, Week 1, 2, 3 and 4
|
|
|
Change From Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) T-Score at Weeks 2 and 4.
Tidsramme: Day -1, Week 2 and 4
|
Brief Assessment Cognition in Schizophrenia (BACS) is specifically designed to measure treatment-related improvements in cognition. A BACS T-score indicating cognitive performance of patients with schizophrenia with a mean of 50 and SD of 10, used for evaluating brain function. Scores are standardized, compared a person's with cognition impairment to a normative group, with scores below 50 indicating poorer performance (lower scores suggest greater difficulty) and above 50 better. |
Day -1, Week 2 and 4
|
|
Number of Abnormal Physical, Neurological, Ophthalmological and Dermatological Examination Findings.
Tidsramme: up to 6 weeks
|
up to 6 weeks
|
|
|
Number of Adverse Events.
Tidsramme: up to 6 weeks
|
All adverse events that occurence during study were assessed. |
up to 6 weeks
|
|
Number of Abnormal Clinically Significant Values in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate) Results.
Tidsramme: up to 6 weeks
|
up to 6 weeks
|
|
|
Number of Abnormal Clinically Significant Values in Laboratory Tests (Hematologic, Clinical Chemistry, Coagulation and Urinalysis) Results.
Tidsramme: up to 6 weeks
|
up to 6 weeks
|
|
|
Number of Abnormal Clinically Significant Findings in Electrocardiogram Results.
Tidsramme: up to 6 weeks
|
The following electrocardiogram parameters were assessed: PR interval, QRS interval, RR interval, QT interval and QTc interval. |
up to 6 weeks
|
|
Number and Intensity of Extrapyramidal Side Effects.
Tidsramme: up to 6 weeks
|
It was assessed by Extrapyramidal Symptom Rating Scale (ESRS). This scale is using to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia. |
up to 6 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 02PDE2019
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .